Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives $20.00 Average Price Target from Brokerages

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $20.00.

ABEO has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Weiss Ratings downgraded Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Finally, Oppenheimer boosted their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th.

Insider Buying and Selling at Abeona Therapeutics

In other news, CFO Joseph Walter Vazzano sold 9,035 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total transaction of $48,698.65. Following the completion of the sale, the chief financial officer owned 453,631 shares of the company’s stock, valued at approximately $2,445,071.09. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total transaction of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares in the company, valued at approximately $6,235,951.08. The trade was a 2.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 63,612 shares of company stock worth $339,171. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Trexquant Investment LP grew its stake in shares of Abeona Therapeutics by 74.1% in the first quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 50,758 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after buying an additional 66,422 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $581,000. Newtyn Management LLC grew its position in shares of Abeona Therapeutics by 26.3% in the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock worth $2,285,000 after buying an additional 100,000 shares during the last quarter. Finally, Simplify Asset Management Inc. raised its holdings in shares of Abeona Therapeutics by 36.7% during the second quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock valued at $3,173,000 after acquiring an additional 150,000 shares in the last quarter. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO opened at $4.95 on Monday. The stock’s 50-day moving average is $5.43 and its 200 day moving average is $5.99. The stock has a market cap of $253.83 million, a price-to-earnings ratio of 7.07 and a beta of 1.45. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.54. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, sell-side analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.